UTHR / United Therapeutics Corporation (BMV) - Forecast, Price Target, Estimates, Predictions

United Therapeutics Corporation
MX ˙ BMV ˙ US91307C1027
Projected Stock Price
No data available.
Projected Revenue

No data available.
Projected Earnings Per Share

6.90 ↑0.48%

Estimated quarterly earnings by December 31, 2026.

Price Target
No data available.
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for United Therapeutics Corporation. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Why Are Analyst Ratings important?

In addition to being able to interpret financial data, stock analysts have connections within the companies they cover that give them access to information retail investors do not have.

Therefore, analyst ratings can help you find opportunities in the market. However, they are guidelines more than recommendations. This is why it’s important to look at analyst ratings over a period of time.

If analysts change their ratings frequently, you should pay close attention to the company’s fundamentals. For example, has there been a significant change to the company’s earnings growth and/or debt?

You should also pay attention to the number of analysts covering a stock over the course of a year. In general, the more analysts who cover the stock give the consensus rating more credibility, but each individual rating less overall weight.

How to Use Analyst Ratings ?

Analyst ratings are one data point for you to consider. Here are some strategies you can use to fine tune your research.

Look at more than one analyst and don’t hesitate to look at analysts that have differing views. This can help challenge any preconceived ideas you have about a stock and point out ways in which your thesis for owning or avoiding a stock may have changed.

Compare a stock’s rating with other stocks in its industry or sector. In some cases, a stock is simply superior to others in its sector. However, at other times, it could be overvalued based on investor sentiment instead of fundamentals.

How are the Fintel Analyst Ratings different?

Analyst ratings by Fintel are presented in close to real-time to stay ahead of generalized information flow. Combined with target price estimates and revenue estimates for the company you have greater accuracy despite market volatility.

Date Analyst Prior Latest
Recommendation
Action
2025-06-11 B of A Securities Neutral Neutral Maintains
2025-04-25 Wells Fargo Overweight Equal-Weight Downgrade
2025-02-27 HC Wainwright & Co. Buy Buy Reiterate
2025-01-08 UBS Buy Buy Maintains
2024-11-01 Goldman Sachs Neutral Neutral Maintains
2024-10-31 Oppenheimer Outperform Outperform Maintains
2024-10-31 Ladenburg Thalmann Buy Buy Maintains
2024-10-31 Argus Research Buy Buy Maintains
2024-10-31 HC Wainwright & Co. Buy Buy Maintains
2024-10-21 TD Cowen Buy Buy Maintains
2024-09-23 Jefferies Buy Buy Maintains
2024-08-28 Oppenheimer Outperform Outperform Maintains
2024-08-20 Wells Fargo Overweight Overweight Maintains
2024-08-01 HC Wainwright & Co. Buy Buy Reiterate
2024-08-01 B of A Securities Underperform Underperform Maintains
2024-07-25 HC Wainwright & Co. Buy Buy Maintains
2024-07-11 TD Cowen Buy Buy Maintains
2024-07-11 Morgan Stanley Overweight Equal-Weight Downgrade
2024-07-08 UBS Buy Buy Maintains
2024-06-12 Wells Fargo Overweight Overweight Maintains
2024-05-21 JP Morgan Overweight Overweight Maintains
2024-05-03 Goldman Sachs Neutral Neutral Maintains
2024-05-02 Oppenheimer Outperform Outperform Maintains
2024-05-02 HC Wainwright & Co. Buy Buy Reiterate
2024-03-07 Wells Fargo Overweight Overweight Maintains
2024-02-22 Wedbush Outperform Outperform Reiterate
2024-02-22 HC Wainwright & Co. Buy Buy Reiterate
2024-02-12 Goldman Sachs Sell Neutral Upgrade
2024-02-05 Leerink Partners Outperform Initiate
2023-11-02 JP Morgan Overweight Overweight Maintains
2023-11-02 Morgan Stanley Overweight Overweight Maintains
2023-11-02 Wedbush Outperform Outperform Maintains
2023-08-03 Morgan Stanley Overweight Overweight Maintains
2023-08-03 Ladenburg Thalmann Buy Buy Maintains
2023-08-03 Wedbush Outperform Outperform Maintains
2023-08-03 HC Wainwright & Co. Buy Buy Reiterate
2023-05-04 Ladenburg Thalmann Buy Maintains
2023-04-21 Argus Research Buy Maintains
2023-04-10 UBS Buy Maintains
2023-04-10 Morgan Stanley Overweight Maintains
2023-02-23 JP Morgan Overweight Maintains
2023-02-23 Morgan Stanley Overweight Maintains
2023-02-23 HC Wainwright & Co. Buy Reiterate
2023-01-11 Argus Research Buy Maintains
2022-12-06 Morgan Stanley Overweight Maintains
2022-12-06 UBS Buy Initiate
2022-12-05 Goldman Sachs Sell Initiate
2022-11-03 JP Morgan Overweight Maintains
2022-11-03 Morgan Stanley Overweight Maintains
2022-11-03 Oppenheimer Outperform Maintains
2022-11-03 HC Wainwright & Co. Buy Maintains
2022-10-11 Morgan Stanley Overweight Initiate
2022-05-24 Jefferies Buy Maintains
2022-05-24 JP Morgan Overweight Maintains
2022-05-24 Wedbush Outperform Maintains
2022-05-24 Credit Suisse Outperform Maintains
2022-05-24 HC Wainwright & Co. Buy Maintains
2022-04-19 JP Morgan Overweight Maintains
2022-02-28 Wedbush Outperform Maintains
2022-02-25 Ladenburg Thalmann Buy Maintains
2022-02-11 BTIG Neutral Initiate
2021-07-14 Argus Research Hold Buy Upgrade
2021-05-06 HC Wainwright & Co. Buy Maintains
2021-04-08 JP Morgan Overweight Maintains
2021-02-22 Credit Suisse Outperform Maintains
2021-02-16 Oppenheimer Outperform Maintains
2021-02-01 HC Wainwright & Co. Neutral Buy Upgrade
2020-07-30 Oppenheimer Outperform Maintains
2020-07-30 Wedbush Outperform Maintains
2020-06-25 Credit Suisse Outperform Maintains
2020-06-25 HC Wainwright & Co. Neutral Maintains
2020-03-10 Jefferies Hold Buy Upgrade
2020-02-27 Cowen & Co. Market Perform Outperform Upgrade
2020-02-13 Credit Suisse Outperform Maintains
2020-01-31 JP Morgan Neutral Overweight Upgrade
2019-08-01 Ladenburg Thalmann Neutral Buy Upgrade
2019-08-01 Jefferies Underperform Hold Upgrade
2019-07-01 Credit Suisse Neutral Outperform Upgrade
2019-05-17 UBS Sell Neutral Upgrade
2019-05-09 Credit Suisse Underperform Neutral Upgrade
2019-05-02 Wedbush Outperform Outperform Maintains
2019-03-01 Barclays Underweight Underweight Maintains
2018-11-19 Credit Suisse Underperform Underperform Maintains
2018-11-02 JP Morgan Neutral Neutral Maintains
2018-11-01 Credit Suisse Underperform Underperform Maintains
2018-10-12 Standpoint Research Hold Buy Upgrade
2018-08-02 Wedbush Outperform Outperform Maintains
2018-07-10 Credit Suisse Neutral Neutral Maintains
2018-05-03 Barclays Underweight Underweight Maintains
2018-05-03 Credit Suisse Neutral Neutral Maintains
2018-04-03 Credit Suisse Underperform Neutral Upgrade
2018-02-22 Credit Suisse Underperform Underperform Maintains
2018-02-22 Barclays Underweight Underweight Maintains
2017-04-03 Cowen & Co. Outperform Market Perform Downgrade
2017-03-30 UBS Sell Initiate
2017-03-16 Credit Suisse Underperform Initiate
2017-03-06 Jefferies Hold Underperform Downgrade
2017-01-19 Standpoint Research Buy Hold Downgrade
2016-12-14 Oppenheimer Outperform Initiate
2016-11-29 Barclays Equal-Weight Underweight Downgrade
2016-10-28 Ladenburg Thalmann Neutral Buy Upgrade
2016-07-29 JP Morgan Neutral Maintains
2016-06-15 H.C. Wainwright Buy Neutral Downgrade
2016-05-24 Argus Buy Hold Downgrade
2016-04-29 Ladenburg Thalmann Buy Neutral Downgrade
2016-02-26 Barclays Equal-Weight Maintains
2016-02-10 Standpoint Research Hold Buy Upgrade
2015-08-19 Wedbush Outperform Maintains
2015-04-29 JP Morgan Neutral Maintains
2015-04-29 Leerink Swann Market Perform Maintains
2015-04-29 Jefferies Hold Maintains
2015-04-01 JP Morgan Neutral Maintains
2015-03-12 Argus Hold Buy Upgrade
2015-02-25 Jefferies Hold Maintains
2015-02-25 JP Morgan Neutral Maintains
2015-01-06 BTIG Research Neutral Initiate
2015-01-06 Barclays Equal-weight Initiate
2014-12-16 JP Morgan Neutral Maintains
2014-12-11 Credit Suisse Neutral Underperform Downgrade
2014-11-03 Argus Buy Hold Downgrade
2014-10-15 Standpoint Hold Buy Upgrade
2014-09-22 Standpoint Research Buy Hold Downgrade
2014-08-29 Wedbush Outperform Maintains
2014-07-30 Credit Suisse Neutral Maintains
2014-06-16 Credit Suisse Market Perform Outperform Upgrade
2014-04-07 Standpoint Research Hold Buy Upgrade
2014-01-05 Goldman Sachs Sell Maintains
2013-12-23 JP Morgan Underweight Neutral Upgrade
2013-12-23 Ladenburg Thalmann Neutral Buy Upgrade
2013-07-30 Standpoint Research Buy Hold Downgrade
2013-07-26 BMO Capital Market Perform Maintains
2013-05-15 Standpoint Research Buy Hold Downgrade
2013-02-27 Deutsche Bank Hold Maintains
2013-02-26 Jefferies Hold Maintains
2013-02-26 Brean Capital Buy Hold Downgrade
2013-02-04 Standpoint Hold Buy Upgrade
2013-01-23 Guggenheim Neutral Initiate
2012-12-13 Goldman Sachs Neutral Sell Downgrade
2012-10-24 JP Morgan Neutral Underweight Downgrade
2012-10-24 BMO Capital Outperform Market Perform Downgrade
2012-07-26 Deutsche Bank Hold Maintains
2012-04-30 Ladenburg Thalmann Buy Maintains
2012-03-26 Canaccord Genuity Buy Initiate
2012-02-14 Brean Capital Buy Maintains
2025-07-08 JP Morgan Overweight Overweight Maintains
2025-06-30 UBS Buy Buy Maintains
2025-04-21 JP Morgan Overweight Overweight Maintains
2025-04-21 B of A Securities Underperform Neutral Upgrade
2025-05-01 Morgan Stanley Equal-Weight Equal-Weight Maintains
2025-05-01 JP Morgan Overweight Overweight Maintains
2025-05-05 HC Wainwright & Co. Buy Buy Reiterate
2025-08-13 UBS Buy Buy Maintains
2025-07-10 Morgan Stanley Equal-Weight Equal-Weight Maintains
2025-09-04 UBS Buy Buy Maintains
2025-07-31 Wells Fargo Equal-Weight Equal-Weight Maintains
2025-07-31 HC Wainwright & Co. Buy Buy Maintains
2025-06-02 Cantor Fitzgerald Overweight Initiate
2025-09-03 Wells Fargo Equal-Weight Equal-Weight Maintains
2025-09-02 B of A Securities Neutral Neutral Maintains
2025-09-02 Jefferies Buy Buy Maintains
Revenue Estimates
No data available.
Earnings Estimates

The forecasted annual earnings of United Therapeutics Corporation in 2032-12-31 is 36.58 per share.

One part of an analyst’s rating is a profit (i.e., earnings) estimate for the current quarter and/or future quarters. The measurement given is earnings per share (EPS). EPS is a metric that indicates how much a company earned as represented by one share of its stock over a specific period (typically three months).

Earnings per Share Calculation

To understand the earnings per share calculation, you must understand net income. Net income is the amount of money a company has left over after deducting appropriate expenses and taxes from its revenues).

The formula for earnings per share is net income divided by the total number of outstanding shares (i.e., available for purchase). For example:

Company A has a net income of $100 million and forty million outstanding shares. The EPS calculation is as follows:

100,000,000/40,000,000 = $2.50 per share

How to use Earnings Per Share in Stock Analysis

Earnings per share is an essential metric for you to consider when deciding to buy a stock. After all, a company with high earnings per share is productive and generates revenue in excess of its operating costs.

However, it’s not the only metric you should use. Metrics like price-to-earnings and debt-to-equity add additional perspective about a company’s health.

You should also be sure to compare a company’s EPS with a company in its sector. However, when you do, be aware that EPS is different and more important than net profit by itself. You may see a company that has a rising net profit. But if its outstanding shares are also rising, then its EPS might be flat or even edging lower.

Update Frequency: Quarterly

Date EPS Average (Quarterly) Number of Analysts (Quarterly) EPS Average (Annual) Number of Analysts (Annually)
2025-09-30 7.29 9 -- --
2025-12-31 7.13 8 28.25 17
2026-03-31 6.36 3 -- --
2026-06-30 6.66 3 -- --
2026-09-30 7.20 3 -- --
2026-12-31 6.90 3 29.80 14
2027-12-31 -- -- 32.07 5
2028-12-31 -- -- 42.22 4
2029-12-31 -- -- 57.80 3
2030-12-31 -- -- 68.76 3
2031-12-31 -- -- 34.10 3
2032-12-31 -- -- 36.58 3
EBITDA Estimates
No data available.
EBIT Estimates
No data available.
Other Listings
DE:UTH €323.50
US:UTHR $400.52
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista